Innovating Against Cancer

Advanced Accelerator Applications, a Novartis company, is an innovative medicines company developing a pipeline of targeted radioligand therapies and precision imaging radioligands for a range of oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently markets one therapeutic drug and several imaging drugs in Europe and the U.S., primarily for clinical use in oncology, cardiology and neurology. AAA has 21 production and research and development facilities, and over 850 employees in 12 countries across Europe and North America.